Sign in Create account
Sign in and upgrade to a paid plan to export futures history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.
Sign in and upgrade to a paid plan to export futures history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.
Sign in and upgrade to a paid plan to export price history as CSV.

Transchem Limited.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 500422
₹416.50
▲ 1.50 (0.36%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
63/100
Moderate
Valuation
21/100
Expensive
Momentum
60/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹510 Cr
PE (TTM)
75.9
Industry median 36.1 (152 companies)
Price to Book
6.1
PEG (TTM)
1.9
Institutions holding %
0.04%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
738.2
Free Cash Flow
₹-2 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
244.44%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
39.17%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
244.51%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
491.22%
as of March 31, 2025
Industry median 14.05% (173 companies)
Current Ratio
21.39
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
1025.76
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
30.12%
as of March 31, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
44.47%
as of March 31, 2025
Industry median 14.22% (181 companies)
Operating Margin (TTM)
Data unavailable.
Return on Assets
4.89%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
6.70%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
5.14%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (5.1%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.4%
Low 400.0000 · High 433.0000
1W return
1.6%
Low 397.0000 · High 433.0000
1M return
18.1%
Low 338.5000 · High 433.0000
52W return
738.2%
Low 300.0000 · High 433.0000
Lifetime High ₹416.5000 (Sept. 30, 2026)
Lifetime Low ₹5.2500 (March 27, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
409.9
10D
402.5
20D
382.3
50D
301.8
100D
214.1
200D
96.8

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

416.50
Pivot
First resistance433.00
Second resistance449.50
Third resistance466.00
First support400.00
Second support383.50
Third support367.00
Day RSI78.9
Day MFI76.9
Day MACD32.63
Day MACD signal37.23

Beta

1M1.44
3M0.88
1Y0.88
3Y0.91

Price change analysis

↑ 18.1%
Over 1 Month
LowHigh
338.50433.00
↑ 738.2%
Over 3 Months
LowHigh
300.00433.00
↑ 738.2%
Over 6 Months
LowHigh
300.00433.00
↑ 738.2%
Over 1 Year
LowHigh
300.00433.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 75.9 (own history: 8.2–20.7)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹5 Cr
Net profit (June 30, 2026)
₹3 Cr
Basic EPS (June 30, 2026)
₹2.7900

Ranks #102 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter56.45%
  • FII/FPI0.03%
  • Public43.51%

Largest holders

NameCategoryShares %Shares
Priyanka Finance Private LimitedPromoter40.1100%4909461
Vijay K ChorariaPromoter16.3400%2000000
Smit Capital Services Private LimitedPublic11.0200%1349329
Firstcorp International LimitedPublic4.4900%549752
Foreign Financial InstitutionPublic0.0300%3200

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 56.45% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings were unchanged at 0.03% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 53 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
10 Feb 2025 PRIYANKA FINANCE PRIVATE LIMITED Bulk Buy 584,387 45.7500 BSE
10 Feb 2025 BRIJWASI SECURITIES PVT. LTD Bulk Sell 585,341 45.7500 BSE
17 Jan 2025 SMIT CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 349,685 44.2500 BSE
17 Jan 2025 ANKIT RAJIDERKUMAR MIGLANI Bulk Sell 350,000 44.2500 BSE
19 May 2023 PRIYANKA FINANCE PRIVATE LIMITED Bulk Buy 96,374 20.0100 BSE
19 May 2023 BAYSWATER ENTERPRISES LIMITED Bulk Sell 100,000 20.0500 BSE
9 Jun 2022 SMIT CAPITAL SERVICES PRIVATE LIMITED Bulk Buy 150,000 20.5400 BSE
9 Jun 2022 PRIYANKA FINANCE PRIVATE LIMITED Bulk Buy 602,774 20.5200 BSE
9 Jun 2022 JMS MINING PRIVATE LIMITED Bulk Sell 755,654 20.5200 BSE
4 Mar 2022 PRIYANKA FINANCE PRIVATE LIMITED Bulk Buy 600,000 24.5700 BSE

All bulk and block deals →

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
12 Sep 2001AGMAgm
1 Nov 2000AGMAgm

All corporate actions →

Corporate Announcements

All 2 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Transchem Ltd-$ - 500422 - Minutes Of The 49Th Annual General Meeting Of The Company
5 Sep 2026 AGM/EGM Transchem Ltd-$ - 500422 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (30.1%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (1025.8x)
  • Strong revenue growth YoY (491.2%)

Weaknesses

  • Low Return on Equity (5.1%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (75.9) -- priced for continued strong execution
  • RSI in overbought territory (78.9)

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Transchem Limited.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.